RSS-Feed abonnieren
DOI: 10.1055/a-2319-0694
Statins in Chronic Liver Disease: Review of the Literature and Future Role
Funding J.N.B. is supported by the Veterans Affairs Career Development Award IK2CX002593–01A1 and the University of California, Los Angeles Comprehensive Liver Research Center.
![](https://www.thieme-connect.de/media/sld/202402/lookinside/thumbnails/10-1055-a-2319-0694_2400015-1.jpg)
Abstract
Chronic liver disease (CLD) is a major contributor to global mortality, morbidity, and healthcare burden. Progress in pharmacotherapeutic for CLD management is lagging given its impact on the global population. While statins are indicated for the management of dyslipidemia and cardiovascular disease, their role in CLD prevention and treatment is emerging. Beyond their lipid-lowering effects, their liver-related mechanisms of action are multifactorial and include anti-inflammatory, antiproliferative, and immune-protective effects. In this review, we highlight what is known about the clinical benefits of statins in viral and nonviral etiologies of CLD and hepatocellular carcinoma (HCC), and explore key mechanisms and pathways targeted by statins. While their benefits may span the spectrum of CLD and potentially HCC treatment, their role in CLD chemoprevention is likely to have the largest impact. As emerging data suggest that genetic variants may impact their benefits, the role of statins in precision hepatology will need to be further explored.
Publikationsverlauf
Accepted Manuscript online:
03. Mai 2024
Artikel online veröffentlicht:
29. Mai 2024
© 2024. Thieme. All rights reserved.
Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA
-
References
- 1 Devarbhavi H, Asrani SK, Arab JP, Nartey YA, Pose E, Kamath PS. Global burden of liver disease: 2023 update. J Hepatol 2023; 79 (02) 516-537
- 2 Morgan S, Grootendorst P, Lexchin J, Cunningham C, Greyson D. The cost of drug development: a systematic review. Health Policy 2011; 100 (01) 4-17
- 3 Lai AG, Chang WH, Parisinos CA. et al. An informatics consult approach for generating clinical evidence for treatment decisions. BMC Med Inform Decis Mak 2021; 21 (01) 281
- 4 Buhaescu I, Izzedine H. Mevalonate pathway: a review of clinical and therapeutical implications. Clin Biochem 2007; 40 (9-10): 575-584
- 5 Endo A, Kuroda M, Tanzawa K. Competitive inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase by ML-236A and ML-236B fungal metabolites, having hypocholesterolemic activity. FEBS Lett 1976; 72 (02) 323-326
- 6 DeBose-Boyd RA. Feedback regulation of cholesterol synthesis: sterol-accelerated ubiquitination and degradation of HMG CoA reductase. Cell Res 2008; 18 (06) 609-621
- 7 Bilheimer DW, Grundy SM, Brown MS, Goldstein JL. Mevinolin and colestipol stimulate receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholesterolemia heterozygotes. Proc Natl Acad Sci U S A 1983; 80 (13) 4124-4128
- 8 Jones PH, Davidson MH, Stein EA. et al; STELLAR Study Group. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol 2003; 92 (02) 152-160
- 9 Thompson PD, Panza G, Zaleski A, Taylor B. Statin-Associated Side Effects. J Am Coll Cardiol 2016; 67 (20) 2395-2410
- 10 Nguyen KA, Li L, Lu D. et al. A comprehensive review and meta-analysis of risk factors for statin-induced myopathy. Eur J Clin Pharmacol 2018; 74 (09) 1099-1109
- 11 Pierno S, Didonna MP, Cippone V. et al. Effects of chronic treatment with statins and fenofibrate on rat skeletal muscle: a biochemical, histological and electrophysiological study. Br J Pharmacol 2006; 149 (07) 909-919
- 12 Hanai J, Cao P, Tanksale P. et al. The muscle-specific ubiquitin ligase atrogin-1/MAFbx mediates statin-induced muscle toxicity. J Clin Invest 2007; 117 (12) 3940-3951
- 13 Atsukawa M, Tsubota A, Shimada N. et al. Effect of fluvastatin on 24-week telaprevir-based combination therapy for hepatitis C virus genotype 1b-infected chronic hepatitis C. Eur J Gastroenterol Hepatol 2014; 26 (07) 781-787
- 14 Bader T, Hughes LD, Fazili J. et al. A randomized controlled trial adding fluvastatin to peginterferon and ribavirin for naïve genotype 1 hepatitis C patients. J Viral Hepat 2013; 20 (09) 622-627
- 15 Gharehbeglou M, Yazdani S, White K, Haeri MR, Masoumzadeh N. Atorvastatin rapidly reduces hepatitis B viral load in combination with tenofovir: a prospective clinical trial. Can J Infect Dis Med Microbiol 2022; 2022: 3443813
- 16 Mangione CM, Barry MJ, Nicholson WK. et al; US Preventive Services Task Force. Statin use for the primary prevention of cardiovascular disease in adults: US Preventive Services Task Force Recommendation Statement. JAMA 2022; 328 (08) 746-753
- 17 Cederberg H, Stančáková A, Yaluri N, Modi S, Kuusisto J, Laakso M. Increased risk of diabetes with statin treatment is associated with impaired insulin sensitivity and insulin secretion: a 6 year follow-up study of the METSIM cohort. Diabetologia 2015; 58 (05) 1109-1117
- 18 Arnett DK, Blumenthal RS, Albert MA. et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2019; 140 (11) e596-e646
- 19 Chou R, Cantor A, Dana T. et al. Statin use for the primary prevention of cardiovascular disease in adults: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA 2022; 328 (08) 754-771
- 20 Rinella ME, Neuschwander-Tetri BA, Siddiqui MS. et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology 2023; 77 (05) 1797-1835
- 21 Newman CB, Preiss D, Tobert JA. et al; American Heart Association Clinical Lipidology, Lipoprotein, Metabolism and Thrombosis Committee, a Joint Committee of the Council on Atherosclerosis, Thrombosis and Vascular Biology and Council on Lifestyle and Cardiometabolic Health; Council on Cardiovascular Disease in the Young; Council on Clinical Cardiology; and Stroke Council. Statin safety and associated adverse events: a scientific statement from the American Heart Association. Arterioscler Thromb Vasc Biol 2019; 39 (02) e38-e81
- 22 Bays H. Statin safety: an overview and assessment of the data–2005. Am J Cardiol 2006; 97 (8A): 6C-26C
- 23 Janičko M, Veselíny E, Leško D, Jarčuška P. Serum cholesterol is a significant and independent mortality predictor in liver cirrhosis patients. Ann Hepatol 2013; 12 (04) 581-587
- 24 Zoli M, Cordiani MR, Marchesini G. et al. Prognostic indicators in compensated cirrhosis. Am J Gastroenterol 1991; 86 (10) 1508-1513
- 25 Kaplan DE, Serper MA, Mehta R. et al; VOCAL Study Group. Effects of hypercholesterolemia and statin exposure on survival in a large national cohort of patients with cirrhosis. Gastroenterology 2019; 156 (06) 1693-1706.e12
- 26 Averbukh LD, Turshudzhyan A, Wu DC, Wu GY. Statin-induced liver injury patterns: a clinical review. J Clin Transl Hepatol 2022; 10 (03) 543-552
- 27 Golomb BA, Evans MA. Statin adverse effects : a review of the literature and evidence for a mitochondrial mechanism. Am J Cardiovasc Drugs 2008; 8 (06) 373-418
- 28 Sung S, Al-Karaghouli M, Kalainy S, Cabrera Garcia L, Abraldes JG. A systematic review on pharmacokinetics, cardiovascular outcomes and safety profiles of statins in cirrhosis. BMC Gastroenterol 2021; 21 (01) 120
- 29 Hui CK, Cheung BMY, Lau GKK. Pharmacokinetics of pitavastatin in subjects with Child-Pugh A and B cirrhosis. Br J Clin Pharmacol 2005; 59 (03) 291-297
- 30 Smith HT, Jokubaitis LA, Troendle AJ, Hwang DS, Robinson WT. Pharmacokinetics of fluvastatin and specific drug interactions. Am J Hypertens 1993; 6 (11, Pt 2): 375S-382S
- 31 Simonson SG, Martin PD, Mitchell P, Schneck DW, Lasseter KC, Warwick MJ. Pharmacokinetics and pharmacodynamics of rosuvastatin in subjects with hepatic impairment. Eur J Clin Pharmacol 2003; 58 (10) 669-675
- 32 Wright AP, Adusumalli S, Corey KE. Statin therapy in patients with cirrhosis. Frontline Gastroenterol 2015; 6 (04) 255-261
- 33 Theile D, Haefeli WE, Seitz HK, Millonig G, Weiss J, Mueller S. Association of liver stiffness with hepatic expression of pharmacokinetically important genes in alcoholic liver disease. Alcohol Clin Exp Res 2013; 37 (Suppl. 01) E17-E22
- 34 Link E, Parish S, Armitage J. et al; SEARCH Collaborative Group. SLCO1B1 variants and statin-induced myopathy–a genome wide study. N Engl J Med 2008; 359 (08) 789-799
- 35 More VR, Cheng Q, Donepudi AC. et al. Alcohol cirrhosis alters nuclear receptor and drug transporter expression in human liver. Drug Metab Dispos 2013; 41 (05) 1148-1155
- 36 Voora D, Baye J, McDermaid A. et al. SLCO1B1*5 allele is associated with atorvastatin discontinuation and adverse muscle symptoms in the context of routine care. Clin Pharmacol Ther 2022; 111 (05) 1075-1083
- 37 Wang LY, Huang YS, Perng CL, Huang B, Lin HC. Statin-induced liver injury in an area endemic for hepatitis B virus infection: risk factors and outcome analysis. Br J Clin Pharmacol 2016; 82 (03) 823-830
- 38 Foster T, Budoff MJ, Saab S, Ahmadi N, Gordon C, Guerci AD. Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: the St Francis Heart Study randomized clinical trial. Am J Gastroenterol 2011; 106 (01) 71-77
- 39 Cho Y, Rhee H, Kim YE. et al. Ezetimibe combination therapy with statin for non-alcoholic fatty liver disease: an open-label randomized controlled trial (ESSENTIAL study). BMC Med 2022; 20 (01) 93
- 40 Abdallah M, Brown L, Provenza J, Tariq R, Gowda S, Singal AK. Safety and efficacy of dyslipidemia treatment in NAFLD patients: a meta-analysis of randomized controlled trials. Ann Hepatol 2022; 27 (06) 100738
- 41 Hatzitolios A, Savopoulos C, Lazaraki G. et al. Efficacy of omega-3 fatty acids, atorvastatin and orlistat in non-alcoholic fatty liver disease with dyslipidemia. Indian J Gastroenterol 2004; 23 (04) 131-134
- 42 Abel T, Fehér J, Dinya E, Eldin MG, Kovács A. Safety and efficacy of combined ezetimibe/simvastatin treatment and simvastatin monotherapy in patients with non-alcoholic fatty liver disease. Med Sci Monit 2009; 15 (12) MS6-MS11
- 43 Athyros VG, Tziomalos K, Gossios TD. et al; GREACE Study Collaborative Group. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet 2010; 376 (9756) 1916-1922
- 44 Kiyici M, Gulten M, Gurel S. et al. Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis. Can J Gastroenterol 2003; 17 (12) 713-718
- 45 Georgescu EF, Georgescu M. Therapeutic options in non-alcoholic steatohepatitis (NASH). Are all agents alike? Results of a preliminary study. J Gastrointestin Liver Dis 2007; 16 (01) 39-46
- 46 Hyogo H, Tazuma S, Arihiro K. et al. Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia. Metabolism 2008; 57 (12) 1711-1718
- 47 Kargiotis K, Athyros VG, Giouleme O. et al. Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome. World J Gastroenterol 2015; 21 (25) 7860-7868
- 48 Lewis JH, Mortensen ME, Zweig S, Fusco MJ, Medoff JR, Belder R. Pravastatin in Chronic Liver Disease Study Investigators. Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: Results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial. Hepatology 2007; 46 (05) 1453-1463
- 49 Abraldes JG, Villanueva C, Aracil C. et al; BLEPS Study Group. Addition of simvastatin to standard therapy for the prevention of variceal rebleeding does not reduce rebleeding but increases survival in patients with cirrhosis. Gastroenterology 2016; 150 (05) 1160-1170.e3
- 50 Abraldes JG, Albillos A, Bañares R. et al. Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial. Gastroenterology 2009; 136 (05) 1651-1658
- 51 Muñoz AE, Pollarsky F, Marino M. et al. Baseline severity and inflammation would influence the effect of simvastatin on clinical outcomes in cirrhosis patients. Dig Dis Sci 2023; 68 (08) 3442-3450
- 52 Vijayaraghavan R, Jindal A, Arora V, Choudhary A, Kumar G, Sarin SK. Hemodynamic effects of adding simvastatin to carvedilol for primary prophylaxis of variceal bleeding: a randomized controlled trial. Am J Gastroenterol 2020; 115 (05) 729-737
- 53 Pose E, Napoleone L, Amin A. et al. Safety of two different doses of simvastatin plus rifaximin in decompensated cirrhosis (LIVERHOPE-SAFETY): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Gastroenterol Hepatol 2020; 5 (01) 31-41
- 54 Blanc JF, Khemissa F, Bronowicki JP. et al; PRODIGE 21 Collaborators. Phase 2 trial comparing sorafenib, pravastatin, their combination or supportive care in HCC with Child-Pugh B cirrhosis. Hepatol Int 2021; 15 (01) 93-104
- 55 Terrault NA, Lok ASF, McMahon BJ. et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology 2018; 67 (04) 1560-1599
- 56 Lingala S, Ghany MG. Natural history of hepatitis C. Gastroenterol Clin North Am 2015; 44 (04) 717-734
- 57 Rusu E, Jinga M, Enache G. et al. Effects of lifestyle changes including specific dietary intervention and physical activity in the management of patients with chronic hepatitis C – a randomized trial. Nutr J 2013; 12: 119
- 58 Bader T, Korba B. Simvastatin potentiates the anti-hepatitis B virus activity of FDA-approved nucleoside analogue inhibitors in vitro. Antiviral Res 2010; 86 (03) 241-245
- 59 Wu C. Hepatitis B virus reactivation associated with atorvastatin. Int J Infect Dis 2013; 17 (11) e1069-e1070
- 60 Hayashi M, Abe K, Fujita M, Okai K, Takahashi A, Ohira H. Hepatitis B virus reactivation in a patient with nonalcoholic steatohepatitis 41 months after rituximab-containing chemotherapy. Intern Med 2019; 58 (03) 375-380
- 61 Harrison SA, Rossaro L, Hu KQ. et al. Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy. Hepatology 2010; 52 (03) 864-874
- 62 Bader T, Fazili J, Madhoun M. et al. Fluvastatin inhibits hepatitis C replication in humans. Am J Gastroenterol 2008; 103 (06) 1383-1389
- 63 Sheridan DA, Bridge SH, Crossey MME. et al. Omega-3 fatty acids and/or fluvastatin in hepatitis C prior non-responders to combination antiviral therapy - a pilot randomised clinical trial. Liver Int 2014; 34 (05) 737-747
- 64 O'Leary JG, Chan JL, McMahon CM, Chung RT. Atorvastatin does not exhibit antiviral activity against HCV at conventional doses: a pilot clinical trial. Hepatology 2007; 45 (04) 895-898
- 65 Kondo C, Atsukawa M, Tsubota A. et al. An open-label randomized controlled study of pegylated interferon/ribavirin combination therapy for chronic hepatitis C with versus without fluvastatin. J Viral Hepat 2012; 19 (09) 615-622
- 66 Atsukawa M, Tsubota A, Kondo C. et al. Combination of fluvastatin with pegylated interferon/ribavirin therapy reduces viral relapse in chronic hepatitis C infected with HCV genotype 1b. J Gastroenterol Hepatol 2013; 28 (01) 51-56
- 67 Yun B, Ahn SH, Yoon JH, Kim BK. Statin use and risk of progression to liver cirrhosis in chronic hepatitis B independent of conventional risk factors: a nationwide study. Hepatol Commun 2022; 6 (09) 2455-2464
- 68 Huang YW, Lee CL, Yang SS. et al. Statins reduce the risk of cirrhosis and its decompensation in chronic hepatitis B patients: a nationwide cohort study. Am J Gastroenterol 2016; 111 (07) 976-985
- 69 Chang FM, Wang YP, Lang HC. et al. Statins decrease the risk of decompensation in hepatitis B virus- and hepatitis C virus-related cirrhosis: a population-based study. Hepatology 2017; 66 (03) 896-907
- 70 Cheung KS, Mak LY, Lam LK. et al. Statins associate with better clinical outcomes in chronic hepatitis B patients with HBsAg seroclearance. Hepatol Int 2021; 15 (04) 881-891
- 71 Butt AA, Yan P, Bonilla H. et al; ERCHIVES (Electronically Retrieved Cohort of HCV Infected Veterans) Study Team. Effect of addition of statins to antiviral therapy in hepatitis C virus-infected persons: Results from ERCHIVES. Hepatology 2015; 62 (02) 365-374
- 72 Simon TG, King LY, Zheng H, Chung RT. Statin use is associated with a reduced risk of fibrosis progression in chronic hepatitis C. J Hepatol 2015; 62 (01) 18-23
- 73 Milazzo L, Meroni L, Galazzi M. et al. Does fluvastatin favour HCV replication in vivo? A pilot study on HIV-HCV coinfected patients. J Viral Hepat 2009; 16 (07) 479-484
- 74 Milazzo L, Caramma I, Mazzali C. et al. Fluvastatin as an adjuvant to pegylated interferon and ribavirin in HIV/hepatitis C virus genotype 1 co-infected patients: an open-label randomized controlled study. J Antimicrob Chemother 2010; 65 (04) 735-740
- 75 Oliver NT, Hartman CM, Kramer JR, Chiao EY. Statin drugs decrease progression to cirrhosis in HIV/hepatitis C virus coinfected individuals. AIDS 2016; 30 (16) 2469-2476
- 76 Byrne DD, Tate JP, Forde KA. et al. Risk of acute liver injury after statin initiation by human immunodeficiency virus and chronic hepatitis C virus infection status. Clin Infect Dis 2017; 65 (09) 1542-1550
- 77 Rosenson RS, Colantonio LD, Burkholder GA, Chen L, Muntner P. Trends in utilization of statin therapy and contraindicated statin use in HIV–infected adults treated with antiretroviral therapy from 2007 through 2015. J Am Heart Assoc 2018; 7 (24) e010345
- 78 Chastain DB, Stover KR, Riche DM. Evidence-based review of statin use in patients with HIV on antiretroviral therapy. J Clin Transl Endocrinol 2017; 8: 6-14
- 79 Wohl DA, McComsey G, Tebas P. et al. Current concepts in the diagnosis and management of metabolic complications of HIV infection and its therapy. Clin Infect Dis 2006; 43 (05) 645-653
- 80 Ikeda M, Abe K, Yamada M, Dansako H, Naka K, Kato N. Different anti-HCV profiles of statins and their potential for combination therapy with interferon. Hepatology 2006; 44 (01) 117-125
- 81 El Kamari V, Hileman CO, Gholam PM, Kulkarni M, Funderburg N, McComsey GA. Statin therapy does not reduce liver fat scores in patients receiving antiretroviral therapy for HIV infection. Clin Gastroenterol Hepatol 2019; 17 (03) 536-542.e1
- 82 Aberg JA, Zackin RA, Brobst SW. et al; ACTG 5087 Study Team. A randomized trial of the efficacy and safety of fenofibrate versus pravastatin in HIV-infected subjects with lipid abnormalities: AIDS Clinical Trials Group Study 5087. AIDS Res Hum Retroviruses 2005; 21 (09) 757-767
- 83 Bremer CM, Bung C, Kott N, Hardt M, Glebe D. Hepatitis B virus infection is dependent on cholesterol in the viral envelope. Cell Microbiol 2009; 11 (02) 249-260
- 84 Dorobantu C, Macovei A, Lazar C, Dwek RA, Zitzmann N, Branza-Nichita N. Cholesterol depletion of hepatoma cells impairs hepatitis B virus envelopment by altering the topology of the large envelope protein. J Virol 2011; 85 (24) 13373-13383
- 85 Lin YL, Shiao MS, Mettling C, Chou CK. Cholesterol requirement of hepatitis B surface antigen (HBsAg) secretion. Virology 2003; 314 (01) 253-260
- 86 Zhao H, Yu Y, Wang Y. et al. Cholesterol accumulation on dendritic cells reverses chronic hepatitis B virus infection-induced dysfunction. Cell Mol Immunol 2022; 19 (12) 1347-1360
- 87 Norouzi A, Taziki S, Najafipasandi A, Mohammadi S, Roshandel G. Rosuvastatin intervention decreased the frequencies of the TIM-3+ population of NK cells and NKT cells among patients with chronic hepatitis B. Iran J Immunol 2022; 19 (03) 255-262
- 88 Li H, Wu K, Tao K. et al. Tim-3/galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patients with hepatitis B virus-associated hepatocellular carcinoma. Hepatology 2012; 56 (04) 1342-1351
- 89 Ju Y, Hou N, Meng J. et al. T cell immunoglobulin- and mucin-domain-containing molecule-3 (Tim-3) mediates natural killer cell suppression in chronic hepatitis B. J Hepatol 2010; 52 (03) 322-329
- 90 Aizaki H, Lee KJ, Sung VMH, Ishiko H, Lai MMC. Characterization of the hepatitis C virus RNA replication complex associated with lipid rafts. Virology 2004; 324 (02) 450-461
- 91 Peng LF, Schaefer EAK, Maloof N. et al. Ceestatin, a novel small molecule inhibitor of hepatitis C virus replication, inhibits 3-hydroxy-3-methylglutaryl-coenzyme A synthase. J Infect Dis 2011; 204 (04) 609-616
- 92 Kapadia SB, Chisari FV. Hepatitis C virus RNA replication is regulated by host geranylgeranylation and fatty acids. Proc Natl Acad Sci U S A 2005; 102 (07) 2561-2566
- 93 Ye J, Wang C, Sumpter Jr R, Brown MS, Goldstein JL, Gale Jr M. Disruption of hepatitis C virus RNA replication through inhibition of host protein geranylgeranylation. Proc Natl Acad Sci U S A 2003; 100 (26) 15865-15870
- 94 Harrison SA, Bedossa P, Guy CD. et al; MAESTRO-NASH Investigators. A Phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. N Engl J Med 2024; 390 (06) 497-509
- 95 Ayada I, van Kleef LA, Zhang H. et al. Dissecting the multifaceted impact of statin use on fatty liver disease: a multidimensional study. EBioMedicine 2023; 87: 104392
- 96 Sfikas G, Psallas M, Koumaras C. et al. Prevalence, diagnosis, and treatment with 3 different statins of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis in military personnel. Do genetics play a role?. Curr Vasc Pharmacol 2021; 19 (05) 572-581
- 97 Blais P, Lin M, Kramer JR, El-Serag HB, Kanwal F. Statins are underutilized in patients with nonalcoholic fatty liver disease and dyslipidemia. Dig Dis Sci 2016; 61 (06) 1714-1720
- 98 Ioannou GN, Haigh WG, Thorning D, Savard C. Hepatic cholesterol crystals and crown-like structures distinguish NASH from simple steatosis. J Lipid Res 2013; 54 (05) 1326-1334
- 99 Ioannou GN, Subramanian S, Chait A. et al. Cholesterol crystallization within hepatocyte lipid droplets and its role in murine NASH. J Lipid Res 2017; 58 (06) 1067-1079
- 100 Min HK, Kapoor A, Fuchs M. et al. Increased hepatic synthesis and dysregulation of cholesterol metabolism is associated with the severity of nonalcoholic fatty liver disease. Cell Metab 2012; 15 (05) 665-674
- 101 Song Y, Liu J, Zhao K, Gao L, Zhao J. Cholesterol-induced toxicity: an integrated view of the role of cholesterol in multiple diseases. Cell Metab 2021; 33 (10) 1911-1925
- 102 Ekstedt M, Franzén LE, Mathiesen UL, Holmqvist M, Bodemar G, Kechagias S. Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes: a histopathological follow-up study. J Hepatol 2007; 47 (01) 135-141
- 103 Taylor RS, Taylor RJ, Bayliss S. et al. Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis. Gastroenterology 2020; 158 (06) 1611-1625.e12
- 104 Nelson A, Torres DM, Morgan AE, Fincke C, Harrison SA. A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: a randomized placebo-controlled trial. J Clin Gastroenterol 2009; 43 (10) 990-994
- 105 Kim D, Adejumo AC, Yoo ER. et al. Trends in mortality from extrahepatic complications in patients with chronic liver disease, from 2007 through 2017. Gastroenterology 2019; 157 (04) 1055-1066.e11
- 106 Adams LA, Lymp JF, St Sauver J. et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005; 129 (01) 113-121
- 107 Postic C, Girard J. Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice. J Clin Invest 2008; 118 (03) 829-838
- 108 Dowman JK, Tomlinson JW, Newsome PN. Pathogenesis of non-alcoholic fatty liver disease. QJM 2010; 103 (02) 71-83
- 109 Orime K, Shirakawa J, Togashi Y. et al. Lipid-lowering agents inhibit hepatic steatosis in a non-alcoholic steatohepatitis-derived hepatocellular carcinoma mouse model. Eur J Pharmacol 2016; 772: 22-32
- 110 Langhi C, Marquart TJ, Allen RM, Baldán A. Perilipin-5 is regulated by statins and controls triglyceride contents in the hepatocyte. J Hepatol 2014; 61 (02) 358-365
- 111 Gao X, Nan Y, Zhao Y. et al. Atorvastatin reduces lipid accumulation in the liver by activating protein kinase A-mediated phosphorylation of perilipin 5. Biochim Biophys Acta Mol Cell Biol Lipids 2017; 1862 (12) 1512-1519
- 112 Marchianò S, Biagioli M, Roselli R. et al. Atorvastatin protects against liver and vascular damage in a model of diet induced steatohepatitis by resetting FXR and GPBAR1 signaling. FASEB J 2022; 36 (01) e22060
- 113 Fraulob JC, Souza-Mello V, Aguila MB, Mandarim-de-Lacerda CA. Beneficial effects of rosuvastatin on insulin resistance, adiposity, inflammatory markers and non-alcoholic fatty liver disease in mice fed on a high-fat diet. Clin Sci (Lond) 2012; 123 (04) 259-270
- 114 Zhang W, Yang X, Chen Y. et al. Activation of hepatic Nogo-B receptor expression - a new anti-liver steatosis mechanism of statins. Biochim Biophys Acta Mol Cell Biol Lipids 2018; 1863 (02) 177-190
- 115 Zhang X, Zhou H, Su Y. Targeting truncated RXRα for cancer therapy. Acta Biochim Biophys Sin (Shanghai) 2016; 48 (01) 49-59
- 116 Ioannou GN, Van Rooyen DM, Savard C. et al. Cholesterol-lowering drugs cause dissolution of cholesterol crystals and disperse Kupffer cell crown-like structures during resolution of NASH. J Lipid Res 2015; 56 (02) 277-285
- 117 Inia JA, Stokman G, Pieterman EJ. et al. Atorvastatin attenuates diet-induced non-alcoholic steatohepatitis in APOE*3-Leiden mice by reducing hepatic inflammation. Int J Mol Sci 2023; 24 (09) 7818
- 118 Van Rooyen DM, Gan LT, Yeh MM. et al. Pharmacological cholesterol lowering reverses fibrotic NASH in obese, diabetic mice with metabolic syndrome. J Hepatol 2013; 59 (01) 144-152
- 119 Seif El-Din SH, El-Lakkany NM, El-Naggar AA. et al. Effects of rosuvastatin and/or β-carotene on non-alcoholic fatty liver in rats. Res Pharm Sci 2015; 10 (04) 275-287
- 120 Yao L, Romero MJ, Toque HA, Yang G, Caldwell RB, Caldwell RW. The role of RhoA/Rho kinase pathway in endothelial dysfunction. J Cardiovasc Dis Res 2010; 1 (04) 165-170
- 121 Trebicka J, Hennenberg M, Laleman W. et al. Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA/Rho-kinase and activation of endothelial nitric oxide synthase. Hepatology 2007; 46 (01) 242-253
- 122 Schierwagen R, Maybüchen L, Hittatiya K. et al. Statins improve NASH via inhibition of RhoA and Ras. Am J Physiol Gastrointest Liver Physiol 2016; 311 (04) G724-G733
- 123 Tripathi DM, Vilaseca M, Lafoz E. et al. Simvastatin prevents progression of acute on chronic liver failure in rats with cirrhosis and portal hypertension. Gastroenterology 2018; 155 (05) 1564-1577
- 124 Chong LW, Hsu YC, Lee TF. et al. Fluvastatin attenuates hepatic steatosis-induced fibrogenesis in rats through inhibiting paracrine effect of hepatocyte on hepatic stellate cells. BMC Gastroenterol 2015; 15: 22
- 125 Wang W, Zhao C, Zhou J, Zhen Z, Wang Y, Shen C. Simvastatin ameliorates liver fibrosis via mediating nitric oxide synthase in rats with non-alcoholic steatohepatitis-related liver fibrosis. PLoS One 2013; 8 (10) e76538
- 126 Kimura Y, Hyogo H, Yamagishi S. et al. Atorvastatin decreases serum levels of advanced glycation endproducts (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: clinical usefulness of AGEs as a biomarker for the attenuation of NASH. J Gastroenterol 2010; 45 (07) 750-757
- 127 Park HS, Jang JE, Ko MS. et al. Statins increase mitochondrial and peroxisomal fatty acid oxidation in the liver and prevent non-alcoholic steatohepatitis in mice. Diabetes Metab J 2016; 40 (05) 376-385
- 128 Rodrigues G, Moreira AJ, Bona S. et al. Simvastatin reduces hepatic oxidative stress and endoplasmic reticulum stress in nonalcoholic steatohepatitis experimental model. Oxid Med Cell Longev 2019; 2019: 3201873
- 129 Bravo M, Raurell I, Hide D. et al. Restoration of liver sinusoidal cell phenotypes by statins improves portal hypertension and histology in rats with NASH. Sci Rep 2019; 9 (01) 20183
- 130 Ciric D, Kravic-Stevovic T, Bumbasirevic V. et al. Effects of metformin and simvastatin treatment on ultrastructural features of liver macrophages in HFD mice. Ultrastruct Pathol 2023; 47 (01) 1-11
- 131 Samy W, Hassanian MA. Paraoxonase-1 activity, malondialdehyde and glutathione peroxidase in non-alcoholic fatty liver disease and the effect of atorvastatin. Arab J Gastroenterol 2011; 12 (02) 80-85
- 132 Longo M, Crosignani A, Battezzati PM. et al. Hyperlipidaemic state and cardiovascular risk in primary biliary cirrhosis. Gut 2002; 51 (02) 265-269
- 133 Takeyama Y, Uehara Y, Anan A. et al. Increased hepatic ABCA1 transporter is associated with hypercholesterolemia in a cholestatic rat model and primary biliary cholangitis patients. Med Mol Morphol 2017; 50 (04) 227-237
- 134 Loaeza-Del Castillo AM, Gaytán-Santillán A, López-Tello A. et al. Patterns of serum lipids derangements and cardiovascular risk assessment in patients with primary biliary cholangitis. Ann Hepatol 2019; 18 (06) 879-882
- 135 Zhang Y, Hu X, Chang J. et al. The liver steatosis severity and lipid characteristics in primary biliary cholangitis. BMC Gastroenterol 2021; 21 (01) 395
- 136 Jang H, Han N, Staatz CE, Kwak JH, Baek IH. Effect on lipid profile and clinical outcomes of obeticholic acid for the treatment of primary biliary cholangitis and metabolic dysfunction-associated steatohepatitis: a systematic review and meta-analysis. Clin Res Hepatol Gastroenterol 2023; 47 (10) 102227
- 137 Siddiqui MS, Van Natta ML, Connelly MA. et al; NASH CRN. Impact of obeticholic acid on the lipoprotein profile in patients with non-alcoholic steatohepatitis. J Hepatol 2020; 72 (01) 25-33
- 138 Stojakovic T, Putz-Bankuti C, Fauler G. et al. Atorvastatin in patients with primary biliary cirrhosis and incomplete biochemical response to ursodeoxycholic acid. Hepatology 2007; 46 (03) 776-784
- 139 Stanca CM, Bach N, Allina J, Bodian C, Bodenheimer Jr H, Odin JA. Atorvastatin does not improve liver biochemistries or Mayo Risk Score in primary biliary cirrhosis. Dig Dis Sci 2008; 53 (07) 1988-1993
- 140 Stojakovic T, Claudel T, Putz-Bankuti C. et al. Low-dose atorvastatin improves dyslipidemia and vascular function in patients with primary biliary cirrhosis after one year of treatment. Atherosclerosis 2010; 209 (01) 178-183
- 141 Ritzel U, Leonhardt U, Näther M, Schäfer G, Armstrong VW, Ramadori G. Simvastatin in primary biliary cirrhosis: effects on serum lipids and distinct disease markers. J Hepatol 2002; 36 (04) 454-458
- 142 Del Puppo M, Galli Kienle M, Crosignani A. et al. Cholesterol metabolism in primary biliary cirrhosis during simvastatin and UDCA administration. J Lipid Res 2001; 42 (03) 437-441
- 143 Cash WJ, O'Neill S, O'Donnell ME. et al. Randomized controlled trial assessing the effect of simvastatin in primary biliary cirrhosis. Liver Int 2013; 33 (08) 1166-1174
- 144 Meireles CZ, Pasarin M, Lozano JJ. et al. Simvastatin attenuates liver injury in rodents with biliary cirrhosis submitted to hemorrhage/resuscitation. Shock 2017; 47 (03) 370-377
- 145 Kim Y, Lee EJ, Jang HK. et al. Statin pretreatment inhibits the lipopolysaccharide-induced epithelial-mesenchymal transition via the downregulation of toll-like receptor 4 and nuclear factor-κB in human biliary epithelial cells. J Gastroenterol Hepatol 2016; 31 (06) 1220-1228
- 146 Desmet VJ. Ludwig symposium on biliary disorders – part I. Pathogenesis of ductal plate abnormalities. Mayo Clin Proc 1998; 73 (01) 80-89
- 147 Park SM. The crucial role of cholangiocytes in cholangiopathies. Gut Liver 2012; 6 (03) 295-304
- 148 Pollo-Flores P, Soldan M, Santos UC. et al. Three months of simvastatin therapy vs. placebo for severe portal hypertension in cirrhosis: a randomized controlled trial. Dig Liver Dis 2015; 47 (11) 957-963
- 149 Bishnu S, Ahammed SM, Sarkar A. et al. Effects of atorvastatin on portal hemodynamics and clinical outcomes in patients with cirrhosis with portal hypertension: a proof-of-concept study. Eur J Gastroenterol Hepatol 2018; 30 (01) 54-59
- 150 Kronborg TM, Schierwagen R, Trošt K. et al. Atorvastatin for patients with cirrhosis. A randomized, placebo-controlled trial. Hepatol Commun 2023; 7 (12) e0332
- 151 Kumar S, Grace ND, Qamar AA. Statin use in patients with cirrhosis: a retrospective cohort study. Dig Dis Sci 2014; 59 (08) 1958-1965
- 152 Chen YC, Li YD, Lu CM, Huang WC, Kao SS, Chen WC. Propranolol use in patients with cirrhosis and refractory ascites: a nationwide study. Saudi J Gastroenterol 2022; 28 (02) 108-114
- 153 Hung TH, Tsai CC, Lee HF. Statin use in cirrhotic patients with infectious diseases: a population-based study. PLoS One 2019; 14 (04) e0215839
- 154 Tapper EB, Parikh ND, Sengupta N. et al. A risk score to predict the development of hepatic encephalopathy in a population-based cohort of patients with cirrhosis. Hepatology 2018; 68 (04) 1498-1507
- 155 Watts KL, Spiteri MA. Connective tissue growth factor expression and induction by transforming growth factor-beta is abrogated by simvastatin via a Rho signaling mechanism. Am J Physiol Lung Cell Mol Physiol 2004; 287 (06) L1323-L1332
- 156 Eberlein M, Heusinger-Ribeiro J, Goppelt-Struebe M. Rho-dependent inhibition of the induction of connective tissue growth factor (CTGF) by HMG CoA reductase inhibitors (statins). Br J Pharmacol 2001; 133 (07) 1172-1180
- 157 Boerma M, Fu Q, Wang J. et al. Comparative gene expression profiling in three primary human cell lines after treatment with a novel inhibitor of Rho kinase or atorvastatin. Blood Coagul Fibrinolysis 2008; 19 (07) 709-718
- 158 Gardner JL, Turner SM, Bautista A, Lindwall G, Awada M, Hellerstein MK. Measurement of liver collagen synthesis by heavy water labeling: effects of profibrotic toxicants and antifibrotic interventions. Am J Physiol Gastrointest Liver Physiol 2007; 292 (06) G1695-G1705
- 159 Klein S, Klösel J, Schierwagen R. et al. Atorvastatin inhibits proliferation and apoptosis, but induces senescence in hepatic myofibroblasts and thereby attenuates hepatic fibrosis in rats. Lab Invest 2012; 92 (10) 1440-1450
- 160 Trebicka J, Hennenberg M, Odenthal M. et al. Atorvastatin attenuates hepatic fibrosis in rats after bile duct ligation via decreased turnover of hepatic stellate cells. J Hepatol 2010; 53 (04) 702-712
- 161 Olteanu D, Nagy A, Dudea M. et al. Hepatic and systemic effects of rosuvastatin on an experimental model of bile duct ligation in rats. J Physiol Pharmacol 2012; 63 (05) 483-496
- 162 Yang JI, Yoon JH, Bang YJ. et al. Synergistic antifibrotic efficacy of statin and protein kinase C inhibitor in hepatic fibrosis. Am J Physiol Gastrointest Liver Physiol 2010; 298 (01) G126-G132
- 163 Zafra C, Abraldes JG, Turnes J. et al. Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis. Gastroenterology 2004; 126 (03) 749-755
- 164 Uschner FE, Ranabhat G, Choi SS. et al. Statins activate the canonical hedgehog-signaling and aggravate non-cirrhotic portal hypertension, but inhibit the non-canonical hedgehog signaling and cirrhotic portal hypertension. Sci Rep 2015; 5: 14573
- 165 Choi SS, Omenetti A, Witek RP. et al. Hedgehog pathway activation and epithelial-to-mesenchymal transitions during myofibroblastic transformation of rat hepatic cells in culture and cirrhosis. Am J Physiol Gastrointest Liver Physiol 2009; 297 (06) G1093-G1106
- 166 Singal AG, Llovet JM, Yarchoan M. et al. AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology 2023; 78 (06) 1922-1965
- 167 Finn RS, Qin S, Ikeda M. et al; IMbrave150 Investigators. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med 2020; 382 (20) 1894-1905
- 168 Mandlik DS, Mandlik SK, Choudhary HB. Immunotherapy for hepatocellular carcinoma: current status and future perspectives. World J Gastroenterol 2023; 29 (06) 1054-1075
- 169 Vogel A, Meyer T, Sapisochin G, Salem R, Saborowski A. Hepatocellular carcinoma. Lancet 2022; 400 (10360): 1345-1362
- 170 Shah RH, Chyou D, Goldberg DS. Impact of major hepatocellular carcinoma policy changes on liver transplantation for hepatocellular carcinoma in the United States. Liver Transpl 2022; 28 (12) 1857-1864
- 171 Younossi Z, Stepanova M, Ong JP. et al; Global Nonalcoholic Steatohepatitis Council. Nonalcoholic steatohepatitis is the fastest growing cause of hepatocellular carcinoma in liver transplant candidates. Clin Gastroenterol Hepatol 2019; 17 (04) 748-755.e3
- 172 Kanwal F, Kramer JR, Asch SM, Cao Y, Li L, El-Serag HB. Long-term risk of hepatocellular carcinoma in HCV patients treated with direct acting antiviral agents. Hepatology 2020; 71 (01) 44-55
- 173 Singal AG, Rich NE, Mehta N. et al. Direct-acting antiviral therapy for hepatitis C virus infection is associated with increased survival in patients with a history of hepatocellular carcinoma. Gastroenterology 2019; 157 (05) 1253-1263.e2
- 174 Choi WM, Kim HJ, Jo AJ. et al. Association of aspirin and statin use with the risk of liver cancer in chronic hepatitis B: a nationwide population-based study. Liver Int 2021; 41 (11) 2777-2785
- 175 Goh MJ, Sinn DH, Kim S. et al. Statin use and the risk of hepatocellular carcinoma in patients with chronic hepatitis B. Hepatology 2020; 71 (06) 2023-2032
- 176 Tsan YT, Lee CH, Wang JD, Chen PC. Statins and the risk of hepatocellular carcinoma in patients with hepatitis B virus infection. J Clin Oncol 2012; 30 (06) 623-630
- 177 Hsiang JC, Wong GLH, Tse YK, Wong VWS, Yip TCF, Chan HLY. Statin and the risk of hepatocellular carcinoma and death in a hospital-based hepatitis B-infected population: a propensity score landmark analysis. J Hepatol 2015; 63 (05) 1190-1197
- 178 Yang X, Wang Y, Luk AOY. et al. Enhancers and attenuators of risk associations of chronic hepatitis B virus infection with hepatocellular carcinoma in type 2 diabetes. Endocr Relat Cancer 2013; 20 (02) 161-171
- 179 Kim HW, Joo YS, Kang SC. et al. Association of statin treatment with hepatocellular carcinoma risk in end-stage kidney disease patients with chronic viral hepatitis. Sci Rep 2022; 12 (01) DOI: 10.1038/s41598-022-14713-w.
- 180 Tsan YT, Lee CH, Ho WC, Lin MH, Wang JD, Chen PC. Statins and the risk of hepatocellular carcinoma in patients with hepatitis C virus infection. J Clin Oncol 2013; 31 (12) 1514-1521
- 181 Vell MS, Loomba R, Krishnan A. et al. Association of statin use with risk of liver disease, hepatocellular carcinoma, and liver-related mortality. JAMA Netw Open 2023; 6 (06) e2320222
- 182 Kraglund F, Christensen DH, Eiset AH, Villadsen GE, West J, Jepsen P. Effects of statins and aspirin on HCC risk in alcohol-related cirrhosis: nationwide emulated trials. Hepatol Commun 2023; 7 (01) e0013
- 183 Kim G, Jang SY, Nam CM, Kang ES. Statin use and the risk of hepatocellular carcinoma in patients at high risk: a nationwide nested case-control study. J Hepatol 2018; 68 (03) 476-484
- 184 McGlynn KA, Divine GW, Sahasrabuddhe VV. et al. Statin use and risk of hepatocellular carcinoma in a U.S. population. Cancer Epidemiol 2014; 38 (05) 523-527
- 185 Tran KT, McMenamin ÚC, Coleman HG. et al. Statin use and risk of liver cancer: evidence from two population-based studies. Int J Cancer 2020; 146 (05) 1250-1260
- 186 Lai SW, Liao KF, Lai HC, Muo CH, Sung FC, Chen PC. Statin use and risk of hepatocellular carcinoma. Eur J Epidemiol 2013; 28 (06) 485-492
- 187 Simon TG, Duberg AS, Aleman S. et al. Lipophilic statins and risk for hepatocellular carcinoma and death in patients with chronic viral hepatitis: results from a nationwide Swedish population. Ann Intern Med 2019; 171 (05) 318-327
- 188 Yi SW, Kim SH, Han KJ, Yi JJ, Ohrr H. Higher cholesterol levels, not statin use, are associated with a lower risk of hepatocellular carcinoma. Br J Cancer 2020; 122 (05) 630-633
- 189 Thrift AP, Natarajan Y, Liu Y, El-Serag HB. Statin use after diagnosis of hepatocellular carcinoma is associated with decreased mortality. Clin Gastroenterol Hepatol 2019; 17 (10) 2117-2125.e3
- 190 Kawata S, Yamasaki E, Nagase T. et al. Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial. Br J Cancer 2001; 84 (07) 886-891
- 191 Jeon CY, Goodman MT, Cook-Wiens G, Sundaram V. Statin use and survival with early-stage hepatocellular carcinoma. Cancer Epidemiol Biomarkers Prev 2016; 25 (04) 686-692
- 192 Morris TJ, Palm SL, Furcht LL, Buchwald H. Effect of lovastatin alone and as an adjuvant chemotherapeutic agent on hepatoma tissue culture-4 cell growth. Ann Surg Oncol 1995; 2 (03) 266-274
- 193 Huether A, Höpfner M, Baradari V, Schuppan D, Scherübl H. EGFR blockade by cetuximab alone or as combination therapy for growth control of hepatocellular cancer. Biochem Pharmacol 2005; 70 (11) 1568-1578
- 194 Riaño I, Martín L, Varela M. et al. Efficacy and Safety of the combination of pravastatin and sorafenib for the Treatment of Advanced Hepatocellular Carcinoma (ESTAHEP Clinical Trial). Cancers (Basel) 2020; 12 (07) 1900
- 195 Jouve JL, Lecomte T, Bouché O. et al; PRODIGE-11 Investigators/Collaborators. Pravastatin combination with sorafenib does not improve survival in advanced hepatocellular carcinoma. J Hepatol 2019; 71 (03) 516-522
- 196 Higashi T, Hayashi H, Kitano Y. et al. Statin attenuates cell proliferative ability via TAZ (WWTR1) in hepatocellular carcinoma. Med Oncol 2016; 33 (11) 123
- 197 Benhammou JN, Qiao B, Ko A, Sinnett-Smith J, Pisegna JR, Rozengurt E. Lipophilic statins inhibit YAP coactivator transcriptional activity in HCC cells through Rho-mediated modulation of actin cytoskeleton. Am J Physiol Gastrointest Liver Physiol 2023; 325 (03) G239-G250
- 198 Wang ST, Ho HJ, Lin JT, Shieh JJ, Wu CY. Simvastatin-induced cell cycle arrest through inhibition of STAT3/SKP2 axis and activation of AMPK to promote p27 and p21 accumulation in hepatocellular carcinoma cells. Cell Death Dis 2017; 8 (02) e2626
- 199 Abukhdeir AM, Park BH. P21 and p27: roles in carcinogenesis and drug resistance. Expert Rev Mol Med 2008; 10: e19
- 200 Relja B, Meder F, Wilhelm K, Henrich D, Marzi I, Lehnert M. Simvastatin inhibits cell growth and induces apoptosis and G0/G1 cell cycle arrest in hepatic cancer cells. Int J Mol Med 2010; 26 (05) 735-741
- 201 Kah J, Wüstenberg A, Keller AD. et al. Selective induction of apoptosis by HMG-CoA reductase inhibitors in hepatoma cells and dependence on p53 expression. Oncol Rep 2012; 28 (03) 1077-1083
- 202 Qi R, An H, Yu Y. et al. Notch1 signaling inhibits growth of human hepatocellular carcinoma through induction of cell cycle arrest and apoptosis. Cancer Res 2003; 63 (23) 8323-8329
- 203 Huang X, Ma J, Xu J, Su Q, Zhao J. Simvastatin induces growth inhibition and apoptosis in HepG2 and Huh7 hepatocellular carcinoma cells via upregulation of Notch1 expression. Mol Med Rep 2015; 11 (03) 2334-2340
- 204 Zhou TY, Zhou YL, Qian MJ. et al. Interleukin-6 induced by YAP in hepatocellular carcinoma cells recruits tumor-associated macrophages. J Pharmacol Sci 2018; 138 (02) 89-95
- 205 Yokohama K, Fukunishi S, Ii M. et al. Rosuvastatin as a potential preventive drug for the development of hepatocellular carcinoma associated with non-alcoholic fatty liver disease in mice. Int J Mol Med 2016; 38 (05) 1499-1506
- 206 Deza Z, Caimi GR, Noelia M, Coli L, Ridruejo E, Alvarez L. Atorvastatin shows antitumor effect in hepatocellular carcinoma development by inhibiting angiogenesis via TGF-β1/pERK signaling pathway. Mol Carcinog 2023; 62 (03) 398-407
- 207 Sutter AP, Maaser K, Höpfner M, Huether A, Schuppan D, Scherübl H. Cell cycle arrest and apoptosis induction in hepatocellular carcinoma cells by HMG-CoA reductase inhibitors. Synergistic antiproliferative action with ligands of the peripheral benzodiazepine receptor. J Hepatol 2005; 43 (05) 808-816
- 208 Zhang W, Wu J, Zhou L, Xie HY, Zheng SS. Fluvastatin, a lipophilic statin, induces apoptosis in human hepatocellular carcinoma cells through mitochondria-operated pathway. Indian J Exp Biol 2010; 48 (12) 1167-1174
- 209 Wang J, Xu Z, Zhang M. Downregulation of survivin expression and elevation of caspase-3 activity involved in pitavastatin-induced HepG 2 cell apoptosis. Oncol Rep 2007; 18 (02) 383-387
- 210 Elleithi YA, El-Gayar AM, Amin MN. Simvastatin induces apoptosis and suppresses hepatocellular carcinoma induced in rats. Appl Biochem Biotechnol 2023; 195 (03) 1656-1674
- 211 Decaudin D, Castedo M, Nemati F. et al. Peripheral benzodiazepine receptor ligands reverse apoptosis resistance of cancer cells in vitro and in vivo. Cancer Res 2002; 62 (05) 1388-1393
- 212 Arasanz H, Gato-Cañas M, Zuazo M. et al. PD1 signal transduction pathways in T cells. Oncotarget 2017; 8 (31) 51936-51945
- 213 Shwe TH, Pothacharoen P, Phitak T, Wudtiwai B, Kongtawelert P. Atorvastatin attenuates programmed death ligand-1 (PD-L1) induction in human hepatocellular carcinoma cells. Int J Mol Sci 2021; 22 (16) 8755
- 214 Cheng Y, Luo R, Zheng H. et al. Synergistic anti-tumor efficacy of sorafenib and fluvastatin in hepatocellular carcinoma. Oncotarget 2017; 8 (14) 23265-23276
- 215 Shao WQ, Zhu WW, Luo MJ. et al. Cholesterol suppresses GOLM1-dependent selective autophagy of RTKs in hepatocellular carcinoma. Cell Rep 2022; 39 (03) 110712
- 216 Wong TL, Ng KY, Tan KV. et al. CRAF methylation by PRMT6 regulates aerobic glycolysis-driven hepatocarcinogenesis via ERK-dependent PKM2 nuclear relocalization and activation. Hepatology 2020; 71 (04) 1279-1296
- 217 Feng J, Dai W, Mao Y. et al. Simvastatin re-sensitizes hepatocellular carcinoma cells to sorafenib by inhibiting HIF-1α/PPAR-γ/PKM2-mediated glycolysis. J Exp Clin Cancer Res 2020; 39 (01) 24
- 218 Mok EHK, Leung CON, Zhou L. et al. Caspase-3-induced activation of SREBP2 drives drug resistance via promotion of cholesterol biosynthesis in hepatocellular carcinoma. Cancer Res 2022; 82 (17) 3102-3115
- 219 Nguyen CDK, Yi C. YAP/TAZ signaling and resistance to cancer therapy. Trends Cancer 2019; 5 (05) 283-296
- 220 Jeon D, Cha HR, Chung SW. et al. Association between statin use and the prognosis of hepatocellular carcinoma after resection: a nationwide cohort study. EClinicalMedicine 2023; 65: 102300
- 221 Khajeh E, Aminizadeh E, Moghadam AD. et al. Association of perioperative use of statins, metformin, and aspirin with recurrence after curative liver resection in patients with hepatocellular carcinoma: a propensity score matching analysis. Cancer Med 2023; 12 (19) 19548-19559
- 222 Yun B, Ahn SH, Oh J, Yoon JH, Kim BK. Statin use is associated with better post-operative prognosis among patients with hepatitis B virus-related hepatocellular carcinoma. Eur J Clin Invest 2023; 53 (04) e13936
- 223 Yang SY, Wang CC, Chen KD. et al. Statin use is associated with a lower risk of recurrence after curative resection in BCLC stage 0-A hepatocellular carcinoma. BMC Cancer 2021; 21 (01) 70
- 224 Nishio T, Taura K, Nakamura N. et al. Impact of statin use on the prognosis of patients with hepatocellular carcinoma undergoing liver resection: a subgroup analysis of patients without chronic hepatitis viral infection. Surgery 2018; 163 (02) 264-269
- 225 Kawaguchi Y, Sakamoto Y, Ito D. et al. Statin use is associated with a reduced risk of hepatocellular carcinoma recurrence after initial liver resection. Biosci Trends 2017; 11 (05) 574-580
- 226 Lee O, Rhu J, Choi GS, Kim JM, Kim K, Joh JW. Impact of statins on hepatocellular carcinoma recurrence after living-donor liver transplantation. Ann Transplant 2022; 27: e935604
- 227 Wu LL, Hsieh MC, Chow JM, Liu SH, Chang CL, Wu SY. Statins improve outcomes of nonsurgical curative treatments in hepatocellular carcinoma patients. Medicine (Baltimore) 2016; 95 (36) e4639
- 228 Dasari BVM, Pathanki A, Hodson J. et al. Propensity-matched analysis of the influence of perioperative statin therapy on outcomes after liver resection. BJS Open 2019; 3 (04) 509-515
- 229 Young SH, Chau GY, Lee IC. et al. Aspirin is associated with low recurrent risk in hepatitis B virus-related hepatocellular carcinoma patients after curative resection. J Formos Med Assoc 2020; 119 (1, Pt 2): 218-229
- 230 Cho Y, Kim MS, Nam CM, Kang ES. Statin use is associated with decreased hepatocellular carcinoma recurrence in liver transplant patients. Sci Rep 2019; 9 (01) 1467
- 231 Becchetti C, Dirchwolf M, Schropp J. et al; Swiss Transplant Cohort Study. Use of statins after liver transplantation is associated with improved survival: results of a nationwide study. Aliment Pharmacol Ther 2022; 56 (07) 1194-1204
- 232 Graf H, Jüngst C, Straub G. et al. Chemoembolization combined with pravastatin improves survival in patients with hepatocellular carcinoma. Digestion 2008; 78 (01) 34-38
- 233 Singal AG, Manjunath H, Yopp AC. et al. The effect of PNPLA3 on fibrosis progression and development of hepatocellular carcinoma: a meta-analysis. Am J Gastroenterol 2014; 109 (03) 325-334
- 234 Lelkes PI, Friedman JE. Interaction of French-pressed liposomes with isolated bovine adrenal chromaffin cells. Characterization of the cell-liposome interactions. J Biol Chem 1985; 260 (03) 1796-1803
- 235 Dongiovanni P, Petta S, Mannisto V. et al. Statin use and non-alcoholic steatohepatitis in at risk individuals. J Hepatol 2015; 63 (03) 705-712